patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_605205 | REC_0005101 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 11.1 | 70 | female | 1 | 21 | 7.7 | 6 | osimertinib 80 mg daily | 9.9 | true | MSI-H | 2026-03-15T05:35:58.108695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197526 | REC_0005102 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.4 | 67 | female | 1 | 70 | 2.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.4 | false | MSS | 2026-03-15T05:35:58.108935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185563 | REC_0005103 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 10.4 | 58 | male | 1 | 17 | 6.5 | 2 | osimertinib 80 mg daily | 19.3 | false | MSS | 2026-03-15T05:35:58.109173+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583349 | REC_0005104 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 5.4 | 63 | female | 1 | 0 | 6.6 | 5 | pembrolizumab 200 mg q3w | 14.1 | false | MSS | 2026-03-15T05:35:58.109403+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780139 | REC_0005105 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 15.9 | 80 | female | 2 | 29 | 6.3 | 7 | osimertinib 80 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:35:58.109637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305169 | REC_0005106 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 14.5 | 60 | male | 1 | 20 | 6.6 | 8 | sotorasib 960 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:58.109877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_151808 | REC_0005107 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 12.3 | 90 | male | 2 | 23 | 6.7 | 6 | alectinib 600 mg BID | 15.5 | true | MSI-H | 2026-03-15T05:35:58.110112+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884094 | REC_0005108 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 17.8 | 65 | female | 0 | 14 | 6.9 | 5 | pembrolizumab 200 mg q3w | 7.2 | true | MSI-H | 2026-03-15T05:35:58.110347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470888 | REC_0005109 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 4.6 | 65 | male | 1 | 60 | 5.9 | 5 | pembrolizumab 200 mg q3w | 8.8 | true | MSS | 2026-03-15T05:35:58.110581+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103809 | REC_0005110 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.9 | 61 | male | 1 | 67 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.4 | false | MSS | 2026-03-15T05:35:58.110888+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_959773 | REC_0005111 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 11.5 | 61 | male | 1 | 29 | 7.3 | 2 | alectinib 600 mg BID | 17.3 | false | MSS | 2026-03-15T05:35:58.111130+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865886 | REC_0005112 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 14.5 | 54 | female | 0 | 11 | 4.1 | 0 | osimertinib 80 mg daily | 17.9 | true | MSS | 2026-03-15T05:35:58.111365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729619 | REC_0005113 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 15.3 | 63 | male | 1 | 8 | 6.2 | 5 | alectinib 600 mg BID | 7.7 | false | MSS | 2026-03-15T05:35:58.111601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349379 | REC_0005114 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 14.2 | 73 | female | 2 | 16 | 4.3 | 1 | osimertinib 80 mg daily | 18.3 | true | MSS | 2026-03-15T05:35:58.111836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_629805 | REC_0005115 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 10.6 | 70 | female | 0 | 26 | 5.7 | 1 | osimertinib 80 mg daily | 19 | false | MSI-H | 2026-03-15T05:35:58.112069+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_301482 | REC_0005116 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.1 | 64 | female | 0 | 62 | 5.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.2 | true | MSS | 2026-03-15T05:35:58.112366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_576308 | REC_0005117 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 14.3 | 59 | female | 0 | 17 | 7.9 | 1 | entrectinib 600 mg daily | 27.5 | false | MSS | 2026-03-15T05:35:58.112609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723557 | REC_0005118 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 22 | 6.1 | 56 | female | 0 | 40 | 6.6 | 0 | carboplatin + paclitaxel + pembrolizumab | 42.7 | false | MSS | 2026-03-15T05:35:58.112854+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826595 | REC_0005119 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 14.8 | 77 | male | 2 | 12 | 5.3 | 7 | osimertinib 80 mg daily | 13.3 | true | MSS | 2026-03-15T05:35:58.113094+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_391613 | REC_0005120 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 17 | 64 | male | 0 | 11 | 7 | 5 | osimertinib 80 mg daily | 6.7 | false | MSI-H | 2026-03-15T05:35:58.113331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_494175 | REC_0005121 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 13.6 | 74 | female | 1 | 13 | 6.6 | 1 | sotorasib 960 mg daily | 21.9 | false | MSS | 2026-03-15T05:35:58.113562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859003 | REC_0005122 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 3.8 | 71 | female | 1 | 25 | 7.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 14.3 | false | MSS | 2026-03-15T05:35:58.113790+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877457 | REC_0005123 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 7 | 68 | female | 0 | 19 | 6 | 6 | alectinib 600 mg BID | 7 | false | MSS | 2026-03-15T05:35:58.114085+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_612220 | REC_0005124 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 6.1 | 65 | female | 1 | 23 | 7.5 | 6 | pembrolizumab 200 mg q3w | 7.5 | true | MSS | 2026-03-15T05:35:58.114319+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_325822 | REC_0005125 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 4.8 | 78 | female | 3 | 29 | 5.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 7 | false | MSS | 2026-03-15T05:35:58.114554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380583 | REC_0005126 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 39 | 13.8 | 45 | female | 0 | 19 | 6.7 | 2 | entrectinib 600 mg daily | 19.4 | false | MSS | 2026-03-15T05:35:58.114792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191327 | REC_0005127 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 10.6 | 63 | male | 1 | 25 | 4.5 | 4 | osimertinib 80 mg daily | 8.6 | true | MSI-H | 2026-03-15T05:35:58.115028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_694109 | REC_0005128 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 8.8 | 56 | male | 0 | 19 | 6.8 | 7 | alectinib 600 mg BID | 13 | false | MSS | 2026-03-15T05:35:58.115261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359671 | REC_0005129 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 34 | 8.1 | 74 | female | 1 | 40 | 3.7 | 5 | pembrolizumab 200 mg q3w | 6.7 | false | MSS | 2026-03-15T05:35:58.115491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_979008 | REC_0005130 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 21.2 | 84 | female | 1 | 12 | 6.4 | 6 | osimertinib 80 mg daily | 14.9 | false | MSS | 2026-03-15T05:35:58.115723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407985 | REC_0005131 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 17 | 3.2 | 73 | female | 2 | 20 | 4.7 | 0 | pembrolizumab 200 mg q3w | 48 | true | MSS | 2026-03-15T05:35:58.115949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735967 | REC_0005132 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 6.7 | 72 | male | 1 | 12 | 8.2 | 6 | alectinib 600 mg BID | 6 | true | MSS | 2026-03-15T05:35:58.116297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149964 | REC_0005133 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.7 | 69 | female | 0 | 30 | 4.6 | 7 | sotorasib 960 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:58.116540+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877983 | REC_0005134 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 17.3 | 64 | male | 1 | 16 | 5.9 | 6 | sotorasib 960 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:58.116779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708692 | REC_0005135 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 7.4 | 58 | male | 0 | 13 | 4.3 | 2 | pembrolizumab 200 mg q3w | 21 | true | MSS | 2026-03-15T05:35:58.117015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_890517 | REC_0005136 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 10.7 | 77 | male | 2 | 14 | 5.8 | 1 | alectinib 600 mg BID | 7.8 | false | MSI-H | 2026-03-15T05:35:58.117327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960394 | REC_0005137 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 19.8 | 65 | male | 0 | 16 | 6.7 | 2 | osimertinib 80 mg daily | 27.7 | true | MSS | 2026-03-15T05:35:58.117574+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997090 | REC_0005138 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.2 | 60 | male | 1 | 72 | 5.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 7.3 | false | MSS | 2026-03-15T05:35:58.117811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234732 | REC_0005139 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 15.5 | 68 | male | 1 | 17 | 5.7 | 2 | osimertinib 80 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:58.118049+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_912307 | REC_0005140 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 7.2 | 66 | female | 0 | 11 | 5.2 | 8 | pembrolizumab 200 mg q3w | 10.1 | true | MSS | 2026-03-15T05:35:58.118279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708876 | REC_0005141 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 14.2 | 78 | female | 2 | 15 | 4.9 | 6 | entrectinib 600 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:58.118511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_591748 | REC_0005142 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 22 | 14.1 | 69 | female | 0 | 20 | 4.3 | 0 | sotorasib 960 mg daily | 37.2 | true | MSS | 2026-03-15T05:35:58.118748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748094 | REC_0005143 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 7.6 | 71 | female | 2 | 22 | 5.6 | 8 | alectinib 600 mg BID | 8.5 | true | MSS | 2026-03-15T05:35:58.118979+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_509821 | REC_0005144 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 16.5 | 76 | female | 1 | 10 | 3 | 7 | sotorasib 960 mg daily | 15.7 | false | MSI-H | 2026-03-15T05:35:58.119210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_820494 | REC_0005145 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 9.8 | 70 | female | 1 | 14 | 6.7 | 5 | pembrolizumab 200 mg q3w | 10.3 | true | MSS | 2026-03-15T05:35:58.119436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165062 | REC_0005146 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 12.1 | 76 | male | 1 | 20 | 6.5 | 3 | osimertinib 80 mg daily | 6.4 | true | MSI-H | 2026-03-15T05:35:58.119670+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769461 | REC_0005147 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 11.3 | 57 | female | 1 | 14 | 4.8 | 6 | entrectinib 600 mg daily | 7.5 | true | MSS | 2026-03-15T05:35:58.119905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837301 | REC_0005148 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12.5 | 69 | female | 1 | 10 | 2.8 | 5 | entrectinib 600 mg daily | 15.4 | true | MSI-H | 2026-03-15T05:35:58.120192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721848 | REC_0005149 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 9.6 | 61 | male | 1 | 17 | 5.6 | 6 | osimertinib 80 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:58.120532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116382 | REC_0005150 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 15.9 | 61 | male | 0 | 21 | 6.2 | 3 | sotorasib 960 mg daily | 15.6 | false | MSI-H | 2026-03-15T05:35:58.120783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358063 | REC_0005151 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 3.5 | 57 | female | 1 | 10 | 5 | 5 | osimertinib 80 mg daily | 4.1 | false | MSS | 2026-03-15T05:35:58.121021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_453461 | REC_0005152 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 6.1 | 88 | male | 2 | 2 | 6.9 | 3 | osimertinib 80 mg daily | 6.9 | false | MSS | 2026-03-15T05:35:58.121253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229425 | REC_0005153 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 16.8 | 61 | male | 1 | 5 | 4.9 | 7 | osimertinib 80 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:35:58.121492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389020 | REC_0005154 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 15.1 | 63 | male | 0 | 4 | 4.9 | 1 | alectinib 600 mg BID | 20.4 | false | MSS | 2026-03-15T05:35:58.121726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302103 | REC_0005155 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 13.7 | 74 | female | 2 | 22 | 5.1 | 2 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:58.121957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996652 | REC_0005156 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 24 | 11.6 | 68 | female | 1 | 9 | 4.2 | 0 | alectinib 600 mg BID | 38.9 | true | MSI-H | 2026-03-15T05:35:58.122189+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563394 | REC_0005157 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 18 | 67 | male | 1 | 18 | 4 | 6 | sotorasib 960 mg daily | 13.6 | false | MSI-H | 2026-03-15T05:35:58.122426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967097 | REC_0005158 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 13.2 | 83 | male | 1 | 33 | 3.8 | 1 | osimertinib 80 mg daily | 23.5 | false | MSS | 2026-03-15T05:35:58.122659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817417 | REC_0005159 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12.8 | 65 | male | 0 | 20 | 7.3 | 3 | sotorasib 960 mg daily | 7.5 | true | MSS | 2026-03-15T05:35:58.122895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124120 | REC_0005160 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 11.2 | 61 | male | 0 | 10 | 7.5 | 3 | entrectinib 600 mg daily | 23 | true | MSI-H | 2026-03-15T05:35:58.123128+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_156343 | REC_0005161 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 7.8 | 76 | female | 3 | 19 | 5.6 | 5 | entrectinib 600 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:58.123359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573265 | REC_0005162 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 20 | 64 | male | 1 | 22 | 3.8 | 4 | entrectinib 600 mg daily | 12.6 | false | MSI-H | 2026-03-15T05:35:58.123658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305253 | REC_0005163 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 14.1 | 67 | male | 1 | 7 | 5.4 | 1 | osimertinib 80 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:58.123899+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546085 | REC_0005164 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 12.3 | 71 | female | 1 | 66 | 5.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.3 | true | MSI-H | 2026-03-15T05:35:58.124241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394232 | REC_0005165 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 12 | 82 | female | 2 | 11 | 4 | 6 | osimertinib 80 mg daily | 7.1 | false | MSI-H | 2026-03-15T05:35:58.124487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981301 | REC_0005166 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7.1 | 61 | female | 0 | 35 | 4.6 | 8 | carboplatin + paclitaxel + pembrolizumab | 6.8 | true | MSS | 2026-03-15T05:35:58.124722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437112 | REC_0005167 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 6.1 | 67 | female | 0 | 17 | 5.7 | 2 | osimertinib 80 mg daily | 22.5 | false | MSS | 2026-03-15T05:35:58.124951+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119244 | REC_0005168 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 9.1 | 74 | female | 1 | 21 | 8.6 | 1 | sotorasib 960 mg daily | 7.9 | true | MSS | 2026-03-15T05:35:58.125180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753588 | REC_0005169 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 31 | 6 | 79 | female | 2 | 15 | 3.8 | 6 | pembrolizumab 200 mg q3w | 8 | false | MSS | 2026-03-15T05:35:58.125415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_335049 | REC_0005170 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 12.6 | 67 | male | 0 | 9 | 5.8 | 1 | osimertinib 80 mg daily | 25.8 | false | MSI-H | 2026-03-15T05:35:58.125651+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790815 | REC_0005171 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 12.9 | 78 | female | 2 | 20 | 7.5 | 3 | entrectinib 600 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:58.125882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507343 | REC_0005172 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 6.5 | 58 | male | 0 | 21 | 6.1 | 8 | entrectinib 600 mg daily | 15.8 | true | MSS | 2026-03-15T05:35:58.126113+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774385 | REC_0005173 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 15.6 | 65 | female | 0 | 15 | 6.5 | 1 | pembrolizumab 200 mg q3w | 13.6 | true | MSS | 2026-03-15T05:35:58.126346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_582602 | REC_0005174 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 12.9 | 76 | female | 1 | 9 | 5.3 | 6 | alectinib 600 mg BID | 13.3 | false | MSI-H | 2026-03-15T05:35:58.126578+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991073 | REC_0005175 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 14.1 | 75 | female | 2 | 15 | 6.6 | 4 | alectinib 600 mg BID | 14.5 | false | MSS | 2026-03-15T05:35:58.126875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_594430 | REC_0005176 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 9.4 | 79 | male | 3 | 17 | 6.4 | 3 | entrectinib 600 mg daily | 10.7 | false | MSS | 2026-03-15T05:35:58.127110+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850963 | REC_0005177 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 16.4 | 59 | male | 1 | 7 | 5.6 | 2 | alectinib 600 mg BID | 13.6 | false | MSI-H | 2026-03-15T05:35:58.127352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225209 | REC_0005178 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 18.1 | 64 | female | 1 | 11 | 5.9 | 9 | sotorasib 960 mg daily | 10.8 | true | MSS | 2026-03-15T05:35:58.127589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_919331 | REC_0005179 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 10 | 70 | female | 2 | 14 | 4.5 | 1 | pembrolizumab 200 mg q3w | 10.1 | false | MSI-H | 2026-03-15T05:35:58.127823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535546 | REC_0005180 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 2.8 | 59 | female | 1 | 68 | 6.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 7.3 | true | MSS | 2026-03-15T05:35:58.128055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456049 | REC_0005181 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 8.2 | 61 | male | 1 | 5 | 6.1 | 5 | sotorasib 960 mg daily | 10 | true | MSS | 2026-03-15T05:35:58.128321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716059 | REC_0005182 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 15 | 10.8 | 73 | male | 1 | 9 | 4 | 4 | osimertinib 80 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:58.128555+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_145356 | REC_0005183 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 11.8 | 76 | female | 2 | 15 | 6.3 | 1 | alectinib 600 mg BID | 17.6 | false | MSI-H | 2026-03-15T05:35:58.128786+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_870589 | REC_0005184 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 10.7 | 78 | male | 2 | 11 | 3.3 | 2 | alectinib 600 mg BID | 12.2 | false | MSI-H | 2026-03-15T05:35:58.129023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535356 | REC_0005185 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 14.9 | 70 | female | 2 | 19 | 7.1 | 1 | entrectinib 600 mg daily | 26.2 | false | MSI-H | 2026-03-15T05:35:58.129254+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139726 | REC_0005186 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.4 | 67 | male | 1 | 47 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.1 | false | MSS | 2026-03-15T05:35:58.129486+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104654 | REC_0005187 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 10 | 71 | female | 2 | 24 | 7.4 | 6 | alectinib 600 mg BID | 12.3 | false | MSI-H | 2026-03-15T05:35:58.129721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182538 | REC_0005188 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.1 | 70 | female | 1 | 55 | 6.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.1 | false | MSS | 2026-03-15T05:35:58.129993+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147946 | REC_0005189 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 21 | 6.9 | 69 | female | 1 | 18 | 6.1 | 0 | pembrolizumab 200 mg q3w | 34.6 | false | MSS | 2026-03-15T05:35:58.130226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684731 | REC_0005190 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 9.2 | 63 | male | 1 | 15 | 8.4 | 7 | sotorasib 960 mg daily | 8 | false | MSS | 2026-03-15T05:35:58.130460+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488138 | REC_0005191 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 15.2 | 63 | female | 0 | 24 | 6 | 7 | sotorasib 960 mg daily | 13.1 | false | MSI-H | 2026-03-15T05:35:58.130698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826163 | REC_0005192 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 20 | 14.9 | 60 | male | 1 | 7 | 4.1 | 0 | osimertinib 80 mg daily | 24.1 | false | MSI-H | 2026-03-15T05:35:58.130929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765990 | REC_0005193 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 34 | 9.2 | 60 | female | 1 | 11 | 4 | 2 | pembrolizumab 200 mg q3w | 24.2 | false | MSS | 2026-03-15T05:35:58.131163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545388 | REC_0005194 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 15.9 | 69 | female | 1 | 17 | 6.2 | 8 | sotorasib 960 mg daily | 11.8 | false | MSI-H | 2026-03-15T05:35:58.131397+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_793944 | REC_0005195 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 6.6 | 67 | female | 1 | 0 | 4.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.4 | true | MSS | 2026-03-15T05:35:58.131630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751929 | REC_0005196 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 13.6 | 54 | male | 0 | 11 | 5.7 | 6 | alectinib 600 mg BID | 5 | false | MSI-H | 2026-03-15T05:35:58.131862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772731 | REC_0005197 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 14.6 | 74 | male | 1 | 23 | 5.1 | 2 | pembrolizumab 200 mg q3w | 6.7 | true | MSI-H | 2026-03-15T05:35:58.132142+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809330 | REC_0005198 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 16.3 | 56 | female | 0 | 13 | 5 | 1 | pembrolizumab 200 mg q3w | 20 | true | MSI-H | 2026-03-15T05:35:58.132384+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_156886 | REC_0005199 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12 | 48 | male | 0 | 0 | 6.9 | 8 | sotorasib 960 mg daily | 15 | false | MSS | 2026-03-15T05:35:58.132625+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750811 | REC_0005200 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 9.6 | 76 | female | 1 | 22 | 3.8 | 1 | sotorasib 960 mg daily | 22.9 | true | MSS | 2026-03-15T05:35:58.132867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.